Cora Biosciences

Cora Biosciences is a biotechnology company developing a first-in-class platform for the targeted degradation of extracellular and membrane-bound proteins. The company's proprietary CORA (Cleavable Outer-surface Receptor Amputation) technology utilizes bifunctional molecules to recruit specific proteases to target receptors, triggering their cleavage and removal from the cell surface. This approach offers a unique mechanism to modulate cell signaling and eliminate disease-driving proteins that are inaccessible to intracellular degradation pathways. Founded by Nobel Laureate Carolyn Bertozzi and Steven Banik, the company is focused on expanding the druggable proteome to treat cancer and autoimmune disorders. Cora Biosciences is backed by leading venture capital firms and is currently advancing its platform through pre-clinical development.